Neurosense Therapeutics LTD F-1 registration statements

The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.

NASDAQ
NeuroSense Therapeutics has filed a registration statement for the resale of up to 10 million ordinary shares by a selling shareholder, with the company potentially receiving up to $30 million from future sales to the same shareholder.
NASDAQ
NeuroSense Therapeutics has filed an amendment to its Form F-1 registration statement, covering the resale of ordinary shares and warrants by selling shareholders.
NASDAQ
NeuroSense Therapeutics has filed a registration statement for the resale of ordinary shares and warrants by selling shareholders, following a recent registered direct offering and private placement.